Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer begins application for Canada's approval of COVID-19 pill

12/01/2021 | 03:25pm EST
Pfizer's COVID-19 pill, Paxlovid, is manufactured and packaged

(Reuters) -Pfizer Inc said on Wednesday it had started the real-time submission of its application seeking Health Canada's approval of its oral COVID-19 antiviral drug candidate.

The pill, PF-07321332, is designed to block a key enzyme needed for the coronavirus to multiply.

The move comes after the Canadian government announced on Tuesday that it was in advanced talks with Pfizer and Merck & Co Inc regarding a purchase agreement for their COVID-19 antiviral drugs, as the country attempts to control the spread of the Omicron coronavirus variant.

The country has identified seven people with the new variant as of Nov. 30.

The drugmaker last month submitted its application seeking U.S. authorization of the experimental pill, which was shown to cut the chance of hospitalization or death for adults at risk of severe disease by 89% in a clinical trial.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Amy Caren Daniel)


© Reuters 2021
All news about PFIZER, INC.
05:42pHealth Canada approves Pfizer antiviral but supply issues expected
AQ
04:04pA look at the latest COVID-19 developments in Canada
AQ
03:34pCanada approves Pfizer COVID drug as hospitalizations rise and kids return to school
AQ
02:13pCanada study of Merck's COVID-19 oral treatment is moving more slowly - health minister
RE
01:22pCanada approves Pfizer COVID drug
AQ
11:23aCanadian Regulator Approves Use of Pfizer Oral Drug for Covid-19
DJ
11:04aGLOBAL MARKETS LIVE : Credit Suisse, Unilever, Pfizer, Volkswagen, Triton...
10:37aCanada approves Pfizer's oral COVID-19 antiviral treatment, deliveries delayed
RE
10:21aHealth Canada To OK Pfizer's COVID-19 Antiviral Pill
MT
10:10aCanada has approved Pfizer's COVID-19 oral antiviral treatment - government website
RE
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 916 M - -
Net income 2021 22 210 M - -
Net Debt 2021 27 661 M - -
P/E ratio 2021 14,4x
Yield 2021 2,88%
Capitalization 308 B 308 B -
EV / Sales 2021 4,10x
EV / Sales 2022 3,31x
Nbr of Employees 78 500
Free-Float -
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 54,95 $
Average target price 57,10 $
Spread / Average Target 3,90%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Susan Silbermann President & General Manager-Pfizer Vaccines
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-6.94%308 427
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.72%323 901
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317
NOVO NORDISK A/S-15.01%218 444